Morgan Stanley Vintage Values Stocks Beat The S&P 500

Have you ever watched a one-year stock list quietly beat the broad market and wondered whether the next version is still worth the attention? I have. That question sat with me after a well-known bank refreshed its annual “hold for twelve months” roster and posted a result that was hard to shrug off. The prior Vintage Values book returned 32.12% from early September 2025 through mid-September 2026, while the S&P 500 managed close to 19%. That gap is 1,316 basis points. In plain English, it is the kind of spread that makes people lean in, even if they know one good year never guarantees the next.

What The New Vintage Values List Is Trying To Do

This is not a day-trading sheet. The idea is almost old-fashioned. Analysts across North America were asked for a single favorite name they would be willing to own for a full year. More than fifty ideas came back. Then the pile was cut to fifteen. Company fundamentals, quantitative screens, macro exposure, industry position, valuation, and risk-reward all went into the blender. I like that mix more than a pure momentum screen, because momentum can look brilliant until it does not.

The firm’s equity strategist put it in a way that stuck with me. The 2027 book has an anti-momentum tilt. These are not simply the names that already worked. They are names the desk thinks still have strong bottom-up drivers. That distinction matters. A list of last year’s winners is a victory lap. A list of businesses with durable engines is a working thesis.

Vintage Values 2027 has an anti-momentum tilt. The stocks on the list are not simply stocks that have worked recently but rather ones identified for their strong bottom-up drivers.

Why The Last Twelve Months Still Matter

Past performance is a tired disclaimer for a reason. Still, ignoring a 32.12% result next to a market that returned nearly 19% would be sloppy. That outperformance did not appear in a vacuum. Quality large caps and growth names had room to run. Liquidity favored scale. Earnings power in a handful of platforms stayed surprisingly resilient.

I’ve found that investors remember the headline number and forget the construction. Construction is the boring part, and it is usually the part that repeats. A process that asks for one high-conviction idea per coverage universe, then filters for quality, industry role, and risk-reward, will never look as exciting as a social-media screen of “hot tickets.” It can still be useful. Sometimes more useful.

Who Stayed And Who Arrived

Twelve of the fifteen names are new. That is a high turnover for a “quality” list, and it tells you the desk is not married to last year’s winners. Only three names survived the cut from the 2026 book into the 2027 book: Amazon, McKesson, and Visa. That trio is not random. You get a mega-cap platform, a healthcare distributor with defensive cash flow, and a payments network that still sits in the plumbing of global spend.

The incoming class is louder. Alphabet and Coca-Cola are the headline additions, one a tech giant and one a consumer-staples giant. Around them sit Apple, Dynatrace, Eli Lilly, Equinix, and Williams Companies, among others. Put those names on a whiteboard and a pattern appears. Scale. Cash. Pricing power. Infrastructure. Healthcare innovation. Software that enterprises actually keep paying for.

Is every name a bargain? No. The desk itself notes that the 2027 roster looks more expensive than the broad market on most measures. That is the uncomfortable part. Quality usually is not cheap when everyone already agrees it is quality. You pay up, or you wait. Waiting can work. Paying up can also work if earnings compound faster than the multiple compresses.

Quality, Large Caps, And A Growth Lean

Sixty percent of the Vintage Values 2027 names sit in the top two quality tiers, versus about 56% for the S&P 500. That is not a night-and-day gap. It is a nudge. The list also leans large cap and growth. In my experience, that combination feels comforting until rates, multiples, or regulation remind you that comfort is not a hedge.

Still, the quality bias is doing real work. Higher-quality businesses tend to have cleaner balance sheets, more pricing power, and fewer “please refinance me” moments. When markets get jumpy, those traits show up in smaller drawdowns. When markets are calm, they can look dull. Dull can be a feature.

• Quality screens favor balance-sheet strength and earnings stability.
• Large-cap exposure reduces single-name liquidity stress.
• Growth exposure keeps the list tied to secular demand, not just mean reversion.
• Valuation is the trade-off, not a footnote.

Alphabet And The Platform Question

Adding Alphabet is not a shock. It is a statement about where profit pools still live. Search, YouTube, cloud, and a widening set of AI products give the company more than one engine. Critics will talk about regulation and traffic mix until the sun goes down. Fair enough. The buy-and-hold case is simpler. Cash flow is large. Reinvestment options are real. The stock can look expensive and still compound if the core franchise does not crack.

I keep coming back to one practical point. A one-year hold in a name like this is less about catching a squeeze and more about owning a business that can absorb bad headlines without losing the plot. That is not romance. It is operating leverage plus distribution.

Coca-Cola And The Case For Boring Cash

Coca-Cola looks like the opposite of Alphabet at first glance. It is not. Both names sell something people keep buying, at scale, through systems that are brutally hard to copy. One sells attention and cloud capacity. The other sells branded refreshment through a distribution machine that has been tuned for decades.

In a list that already tilts growth, a staples giant does useful ballast. Pricing power in consumer brands is not magic. It is brand equity plus route-to-market. When inflation cools or heats, that combination still gives management room. Perhaps the most interesting aspect is how unfashionable that sounds. Unfashionable cash flow has bailed out more portfolios than hot narratives have.

Amazon, Visa, And McKesson As The Holdovers

Amazon remaining on the list is almost expected, and that is why it is easy to underthink. Retail, advertising, and cloud still form a three-legged stool. One leg can wobble without the whole thing falling over. That is rare. A one-year horizon in Amazon is really a bet that operating discipline stays in the room and that cloud demand does not roll over.

Visa is the quieter compounder. Networks do not need to invent a new product every quarter to stay relevant. They need volume, reliability, and the confidence of banks and merchants. That is a different kind of growth. It is less theatrical and often more durable.

McKesson sits in the unglamorous middle of healthcare. Distribution is not a dinner-party topic. It is also hard to dislodge when scale, compliance, and relationships are the moat. If the rest of the list is about platforms and pipelines, McKesson is about keeping the shelves stocked. Someone has to do that work.

Healthcare Innovation Meets Infrastructure

Eli Lilly on a one-year list is a reminder that healthcare can behave like growth tech when a franchise is firing. Obesity and diabetes treatments changed the conversation around the company. The risk is obvious. Expectations are high. Valuation is not shy. Policy and competition can bruise a multiple overnight. The opportunity is also obvious. If demand stays stronger for longer, earnings can grow into the price.

Equinix is a different flavor of the same era. Data needs a home. Interconnection needs a landlord. A digital-infrastructure name on a quality list is a bet that cloud, AI workloads, and enterprise networking keep paying rent. Dynatrace plays a related game on the software side: if systems get more complex, observability stops being optional.

Williams Companies pulls the list toward energy midstream. Pipelines and gathering systems are not meme material. They can produce fee-like cash flow tied to volumes rather than daily commodity fireworks. In a book full of growth multiples, that cash-flow shape is a useful contrast.

How The Selection Process Actually Filters Names

Fifty-plus analyst favorites sounds messy. It is. That is the point. A coverage universe is full of local knowledge. The job of the strategist is to keep the local knowledge and kill the pet projects. Fundamentals first. Then quant. Then macro mapping. Then industry structure. Then valuation and the ugly question: what do you lose if you are wrong?

1. Collect one high-conviction idea from each relevant desk.
2. Score business quality, not just recent price action.
3. Check how the name behaves if growth, rates, or the dollar shift.
4. Ask whether the industry structure still favors the incumbent.
5. Cut anything whose downside is too wide for a one-year hold.

That last step is where a lot of “interesting” stocks die. Interesting is not the same as ownable. A one-year list has no room for a story that needs three miracles and a friendly multiple.

The Valuation Problem Nobody Should Soft-Pedal

The 2027 list is richer than the market on most metrics. I will not dress that up. Paying a premium for quality is a classic investor habit. It works when the premium is earned by faster compounding. It fails when the premium is just popularity wearing a lab coat.

So what do you do with an expensive quality book? You stop treating it like a dare. Position size matters more when starting multiples are high. A 15-name list can still be a research menu rather than a mandate to own every line. Some readers will take two or three ideas. Some will use the themes and ignore the exact tickers. That is allowed. In fact, it is often wiser.

Simple holding frame for a rich quality list:
  40% process and business quality
  30% starting valuation and downside
  30% time horizon and position size

Anti-Momentum Does Not Mean Anti-Performance

People hear “anti-momentum” and assume the list is full of laggards. That is not the claim. The claim is that recent price victory was not the admission ticket. A stock can have worked and still qualify if the next twelve months have a fundamental engine. A stock can have lagged and still qualify if the engine is underappreciated. The filter is the driver, not the rear-view mirror.

I’ve watched investors confuse momentum with quality because the two often travel together in bull tapes. They are not twins. Momentum is a crowd. Quality is a balance sheet, a moat, and a reinvestment runway. When the crowd leaves, you find out which one you actually owned.

What A One-Year Horizon Quietly Changes

Twelve months is long enough to be more than a trade and short enough to be more than a forever compounder speech. Earnings reports will land. Guidance will shift. A product cycle can bloom or stall. That horizon punishes thesis drift. If you cannot explain why the next four quarters should be acceptable, you probably do not belong in the name.

It also punishes overtrading. The last book beat the index by a wide margin while asking investors to sit still. Sitting still is underrated. It is also uncomfortable when a new narrative pops up every Monday. A written one-year mandate is a cheap behavioral tool. You can still sell if the thesis breaks. You just need a better reason than boredom.

Risks That Sit Inside A “Quality” Label

Quality is not armor. Mega-cap platforms carry regulatory and political risk. Healthcare franchises carry policy and pipeline risk. Infrastructure names carry rate and capex risk. Staples names carry volume and FX risk. A tidy label can hide a messy sensitivity table.

• Multiple compression if rates stay higher for longer.
• Policy shocks in healthcare and large-cap tech.
• Capex cycles that outrun returns in digital infrastructure.
• Consumer fatigue that hits even strong brands.
• Concentration risk if too many names lean on the same macro factor.

None of that makes the list unusable. It makes the list honest. A portfolio that looks defensive on quality scores can still be aggressive on valuation. Hold both thoughts at once.

How I Would Use A List Like This Without Turning It Into A Cult

I would not copy all fifteen names and call it a personality. I would map each name to a job. Amazon and Alphabet can be growth compounders. Visa can be the tollbooth. Coca-Cola and McKesson can be ballast. Eli Lilly can be the high-expectation special situation. Equinix and Williams can be infrastructure cash. Dynatrace can be the software pick with cyclical enterprise spend risk attached.

Then I would ask a blunt question. If this name dropped 20% in three months for no thesis-breaking reason, would I want more, the same, or an exit? If the answer is “I have no idea,” the position is too big or the homework is too thin.

A stock list is a set of arguments, not a permission slip to stop thinking.

What The Outperformance Does Not Prove

A 1,316-basis-point win is impressive. It does not prove the next book will win. It does not prove expensive quality is always the right side of the trade. It does not prove large-cap growth is a permanent regime. It proves one process, in one window, beat one index. That is worth respect. It is not worth worship.

Markets love to turn a good year into a slogan. Resist that. Look at the overlap. Look at the turnover. Look at the valuation gap versus the index. Look at the sector mix. Those details will tell you more than the trophy number.

A Practical Checklist Before You Act

If you are going to use any of this, keep the checklist short enough to actually use.

1. Write the one-year thesis in two sentences.
2. Write the invalidation point in one sentence.
3. Compare valuation to the stock’s own history, not only to the index.
4. Check concentration if you already own similar mega-caps.
5. Size the position for a bad quarter, not a perfect quarter.

That is not fancy. Fancy is how people talk themselves into oversized bets. Simple is how they stay solvent long enough for compounding to matter.

The Quiet Takeaway

The last Vintage Values book beat the S&P 500 by a wide margin. The new book keeps Amazon, McKesson, and Visa, then rotates hard toward a fresh mix of platforms, staples, healthcare, software, and infrastructure. It is quality-heavy, large-cap heavy, growth-leaning, and not cheap. The anti-momentum label is the part I keep circling. It asks you to care about the next set of drivers instead of last year’s applause.

Will every new name work? Of course not. A fifteen-stock list is still a human document. Analysts can be early. They can be late. They can fall in love with a franchise. That is why the useful move is not to memorize tickers. It is to steal the process: one high-conviction idea, a quality filter, a real discussion of downside, and a horizon long enough to let a business do some work.

If you came here hunting for a shortcut, you will not find one that stays clean. If you came here for a sharper way to think about a one-year hold in expensive quality names, you already have the raw material. The market will grade the 2027 list in public. Until then, the edge is not the headline return from last year. The edge is whether you can tell the difference between a business that earned its spot and a name that merely survived a good tape.